BACKGROUND: The isoprostane 8,12-iso-iPF(2alpha)-VI, a specific marker of in vivo lipid peroxidation, is increased in Alzheimer disease (AD). The pathological changes associated with AD have a long silent phase before the appearance of clinical symptoms. Several studies have shown that AD is preceded by a prodromal phase characterized by mild cognitive impairment (MCI). OBJECTIVE: To investigate levels of this biomarker in subjects with MCI. DESIGN AND MAIN OUTCOME MEASURES: Using gas chromatography-mass spectrometry analysis, we measured 8,12-iso-iPF(2alpha)-VI levels in urine, plasma, and cerebrospinal fluid of patients with AD, subjects with MCI, and cognitively normal elderly subjects. SETTING AND PATIENTS: Subjects attending the Memory Disorders Clinic. RESULTS: We found significantly higher 8,12-iso-iPF(2alpha)-VI levels in cerebrospinal fluid, plasma, and urine of subjects with MCI compared with cognitively normal elderly subjects. CONCLUSIONS: These results imply that individuals with MCI have increased brain oxidative damage before the onset of symptomatic dementia. Measurement of this isoprostane may identify a subgroup of patients with MCI with increased lipid peroxidation who are at increased risk to progress to symptomatic AD.
BACKGROUND: The isoprostane8,12-iso-iPF(2alpha)-VI, a specific marker of in vivo lipid peroxidation, is increased in Alzheimer disease (AD). The pathological changes associated with AD have a long silent phase before the appearance of clinical symptoms. Several studies have shown that AD is preceded by a prodromal phase characterized by mild cognitive impairment (MCI). OBJECTIVE: To investigate levels of this biomarker in subjects with MCI. DESIGN AND MAIN OUTCOME MEASURES: Using gas chromatography-mass spectrometry analysis, we measured 8,12-iso-iPF(2alpha)-VI levels in urine, plasma, and cerebrospinal fluid of patients with AD, subjects with MCI, and cognitively normal elderly subjects. SETTING AND PATIENTS: Subjects attending the Memory Disorders Clinic. RESULTS: We found significantly higher 8,12-iso-iPF(2alpha)-VI levels in cerebrospinal fluid, plasma, and urine of subjects with MCI compared with cognitively normal elderly subjects. CONCLUSIONS: These results imply that individuals with MCI have increased brain oxidative damage before the onset of symptomatic dementia. Measurement of this isoprostane may identify a subgroup of patients with MCI with increased lipid peroxidation who are at increased risk to progress to symptomatic AD.
Authors: Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry Journal: Neurotox Res Date: 2012-06-06 Impact factor: 3.911
Authors: A-Ryeong Gwon; Jong-Sung Park; Thiruma V Arumugam; Yong-Kook Kwon; Sic L Chan; Seol-Hee Kim; Sang-Ha Baik; Sunghee Yang; Young-Kwang Yun; Yuri Choi; Saerom Kim; Sung-Chun Tang; Dong-Hoon Hyun; Aiwu Cheng; Charles E Dann; Michel Bernier; Jaewon Lee; William R Markesbery; Mark P Mattson; Dong-Gyu Jo Journal: Aging Cell Date: 2012-04-09 Impact factor: 9.304
Authors: Patrizia De Sarno; Svetlana A Shestopal; Taj D King; Anna Zmijewska; Ling Song; Richard S Jope Journal: J Biol Chem Date: 2003-01-21 Impact factor: 5.157
Authors: M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico Journal: J Neurol Date: 2007-11-14 Impact factor: 4.849
Authors: Marta Leirós; Eva Alonso; Jon A Sanchez; Mostafa E Rateb; Rainer Ebel; Wael E Houssen; Marcel Jaspars; Amparo Alfonso; Luis M Botana Journal: ACS Chem Neurosci Date: 2013-11-19 Impact factor: 4.418